Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Our expertise is in designing inhibitors of protein-protein interactions (PPIs) to restore apoptosis, or programmed cell death. We have eight clinical candidates in Phase 1 or 2 studies in the U.S., Australia and China. Our clinical candidates include a novel Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).
Ascentage actively seeks co-development and co-promotion partnerships as part of a comprehensive strategy to accelerate the development of our lead assets in the global marketplace. We are continually looking to identify partners with portfolios that are complementary to the specific mechanisms of action of our therapeutic candidates.